Novavax CEO Jacobs exercises RSUs, shares withheld
Jacobs John C reported disposition transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jacobs John C reported disposition transactions in this Form 4 filing.
Novavax Inc. President and CEO John C. Jacobs exercised 83,197 Restricted Stock Units into an equal number of common shares on January 23, 2026. On the same date, 39,132 common shares were delivered to satisfy tax obligations. Following these transactions, he holds 180,797 common shares directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 83,197 | $0.00 | $0.00 |
| Exercise | Common Stock | 83,197 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 39,132 | $9.17 | $359K |
Footnotes (1)
- F1. One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date.
Key Figures
Key Terms
Restricted Stock Units financial
tax-withholding disposition financial
derivative security financial
grant date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Novavax (NVAX) CEO John C. Jacobs report in this Form 4?
What type of securities did the Novavax (NVAX) CEO exercise in this report?
When did the Novavax (NVAX) CEO's RSUs convert into common stock?
AI-generated analysis. How Rhea-AI works. Not financial advice.